UKCPA viewpoint: Tofacitinib raises risk of PE

Learning

UKCPA viewpoint: Tofacitinib raises risk of PE

In Learning

There is an increased risk of pulmonary embolism in patients receiving tofacitinib 10mg twice daily says Mikin Patel, a gastroenterology lead pharmacist

Tofacitinib is a frst generation non-selective janus-kinase (JAK) inhibitor that is currently licensed for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), with a recommended dose of 5mg twice daily.

In 2018 the European Medicines Agency (EMA) also approved tofacitinib as a treatment for ulcerative colitis (UC) with a recommended dose of 10mg twice daily for the frst eight weeks and thereafter 5mg twice daily.

Currently, the dosing of 10mg twice daily is only licensed in UC but an openlabel clinical trial (Study A3921133) has evaluated the safety of both tofacitinib 5mg and tofacitinib 10mg twice daily compared with a tumour necrosis factor inhibitor (TNFi) in RA patients.

Pulmonary embolism

The trial identifed that the overall incidence of pulmonary embolism (PE) was fve-fold higher in the tofacitinib 10mg twice daily arm of the study compared with the TNF inhibitor arm, and approximately three-fold higher than tofacitinib in other studies across the tofacitinib programme.

Based on this safety concern, patients receiving tofacitinib, irrespective of indication, should be monitored for the signs and symptoms of PE and be advised to seek medical attention immediately if they experience them.

The EMA Pharmacovigilance Risk Assessment Committee (PRAC) – the committee responsible for the evaluation of safety issues for human medicines – is recommending that the 10mg twice daily dose is not prescribed to patients who are at high risk of PE until the risk has been reviewed.

If a patient has known rheumatoid arthritis, psoriatic arthritis or ulcerative colitis, and is under the care of a consultant from secondary care, it is important to check whether they are taking tofacitinib.

These patients should be monitored for the signs and symptoms of pulmonary embolism, and be advised to seek medical attention if this is the case.

Next steps

An in-depth review is currently being carried out by the Pharmacovigilance Risk Assessment Committee, which will subsequently make a set of recommendations. These recommendations will then be forwarded to the Committee for Medicinal Products for Human Use (CHMP), which will adopt an opinion.

The fnal stage in the process is the adoption by the European Commission of a legally binding decision.

For more information about the UKCPA visit their website.

This column is produced in association with the UKCPA. The views expressed are those of the author and are not necessarily those of either Pharmacy Magazine or the UKCPA.

Record my learning outcomes

Learning

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Learning

CPPE: New places on Leading for Change programme

The programme aims to help experienced pharmacy professionals reflect on and develop their leadership style.

1 Min Article

bookmark_icon_off
Learning

UKCPA viewpoint: Tofacitinib raises risk of PE

There is an increased risk of pulmonary embolism in patients receiving tofacitinib 10mg twice daily.

1 Min Article

bookmark_icon_off
Learning

Applications open for foundation pharmacist training

CPPE has opened applications for the newest intake of pharmacists on its foundation pharmacist training pathway. Limited places are available.

1 Min Article

bookmark_icon_off
Learning

UKCPA: Initiatives to tackle penicillin allergy

Researchers in the NHS are looking at allergies, in particular penicillin allergy, says pharmacist Yogini Jani.

1 Min Article

bookmark_icon_off
Learning

CPPE: New gateway page on DMIRS

CPPE is introducing learning resources for the Digital Minor Illness Referral Service (DMIRS)

1 Min Article

bookmark_icon_off
Learning

UKCPA: What is autonomic dysreflexia?

Autonomic dysreflexia (AD) deserves a wider level of understanding among pharmacists.

1 Min Article

Recommended Learning

bookmark_icon_off
Sponsored education

Managing hay fever: help meet your customers' needs

This module will improve your hay fever knowledge, helping you to understand its impact on sufferers and recommend the right products to ease symptoms

15 Min Module

bookmark_icon_off
Sponsored education

Common Childhood Illnesses

This interactive video will test and reinforce your knowledge so you can confidently advise parents on common childhood illnesses, such as teething, earache, coughs and colds.

10 Min Module

bookmark_icon_off
Sponsored education

Confident pet health conversations

Learn 3 key steps to having more confident conversations with customers about pet health products.

3 Min Module

Sponsored education

Dry eye consultations

Work through a customer consultation to determine the possible cause of stinging, gritty eyes and recommend an effective treatment to help ease these symptoms.

15 Min Module

bookmark_icon_off
Sponsored education

Supporting customers to sleep better

Explore the rotating pack shot to find out more about Nytol Liquid Caramel Flavour, a clinically-proven alternative to sleeping tablets, and understand how you can support customers to sleep better.

5 Min Module

bookmark_icon_off
Sponsored education

Understanding constipation treatments

Discover the key benefits of different types of laxatives, and the right questions to ask customers to ensure you know which to recommend

10 Min Module